Literature DB >> 1919848

Effects of indomethacin on demineralized bone-induced heterotopic ossification in the rat.

P E DiCesare1, M E Nimni, L Peng, M Yazdi, D T Cheung.   

Abstract

Indomethacin inhibits bone formation when treatment is initiated before the implantation of demineralized bone matrix (DBM). For the inhibition of bone induction to occur, indomethacin treatment had to be initiated 6 h or more before implantation of DBM. Initiating the drug treatment at or after the time of DBM implantation had no effects on the amounts of new bone formed. The inhibition by indomethacin is dose related over a range between 0.04 and 4 mg/kg body weight. Recovered day-1 DBM implants, transplanted into indomethacin pre- and posttreated syngeneic rats, formed bone at the same rate as controls did. However, recovered day-1 DBM implants lyophilized before transplantation showed decreased bone formation but significant dystrophic calcification as judged by a lower alkaline phosphatase activity and an elevated calcium content.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919848     DOI: 10.1002/jor.1100090611

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  6 in total

1.  Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.

Authors:  Sayantani Sinha; Kenta Uchibe; Yu Usami; Maurizio Pacifici; Masahiro Iwamoto
Journal:  Bone       Date:  2016-02-15       Impact factor: 4.398

2.  Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.

Authors:  Ryuichiro Yamamoto; Masaki Matsushita; Hiroshi Kitoh; Akio Masuda; Mikako Ito; Takenobu Katagiri; Tatsushi Kawai; Naoki Ishiguro; Kinji Ohno
Journal:  J Bone Miner Metab       Date:  2012-08-24       Impact factor: 2.626

3.  Neurological symptoms in individuals with fibrodysplasia ossificans progressiva.

Authors:  Joseph A Kitterman; Jonathan B Strober; Lixin Kan; David M Rocke; Amanda Cali; Jeannie Peeper; Jennifer Snow; Patricia L R Delai; Rolf Morhart; Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

Review 4.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

Review 5.  Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities.

Authors:  Maurizio Pacifici
Journal:  Curr Opin Pharmacol       Date:  2018-03-31       Impact factor: 5.547

Review 6.  Neurological heterotopic ossification: novel mechanisms, prognostic biomarkers and prophylactic therapies.

Authors:  Ker Rui Wong; Richelle Mychasiuk; Terence J O'Brien; Sandy R Shultz; Stuart J McDonald; Rhys D Brady
Journal:  Bone Res       Date:  2020-12-09       Impact factor: 13.567

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.